The success of monoclonal antibodies in managing wide range of challenging diseases has prompted the further research and development activities in this sector.
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Detailed Market Sales & Trends Insight
- Quarterly & Yearly Sales Insight Of Approved Antibodies Till Q1 2022
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
Download Report:
The success of monoclonal antibodies in managing wide range of challenging diseases has prompted the further research and development activities in this sector. In last few years, bispecific antibodies have entered the market which can simultaneously bind two separate and unique antigens (or different epitopes of the same antigen). The therapeutic effects of bispecific antibodies have shown superior effect in comparison to monoclonal antibodies with broad applications for tumor immunotherapy as well as for the treatment of other diseases.
To date, four bispecific antibodies have been approved for regulatory bodies. Blincyto (Blinatumomab) developed by Amgen was the bispecific antibody approved by US FDA in 2014. Blincyto is a novel bispecific CD19 directed CD3 T-cell engager which is indicated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. Later in 2017, Genentech developed Hemlibra which is a bispecific factor IXA and factor X-directed antibody indicated to prevent or reduce the frequency of bleeding episodes in patients with Hemophilia A. In 2021, Rybrevant (Amivantamab) developed by Janssen Pharmaceuticals was also granted approval. Recently in January 2022, US FDA has approved Vabsymo (faricimab) developed by Roche for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
The high adoption rates in the global market has further surged the research and development activities in this domain. For instance, Janssen Pharmaceutical has recently submitted biologics license application to the FDA for teclistamab as treatment of patients with relapsed or refractory multiple myeloma. Teclistamab is a novel, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3. In addition, US FDA has cleared investigational new drug application to Compass Therapeutics to initiate a global Phase 2 clinical trial for CTX-009 in patients who have advanced Biliary Tract Cancers (BTC) in the United States and South Korea. CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A). These rising trends in the global bispecific antibody market points towards the positive future of bispecific antibodies in management of wide range of diseases.
The growing demand for bispecific antibodies for the treatment of infectious diseases, cancer tumors, bacterial infections, and cancer diagnostics is one of the major factors fostering the growth of bispecific antibody market. Since the numbers of cancer patients and infectious diseases are growing, the requirement to cure the patients has increased. Apart from this, the increasing competition among pharmaceutical companies to develop novel bispecific antibodies will also drive the growth of market. The major companies involved in global bispecific antibody market include Amgen, Pfizer, Roche, Sanofi, Bristol Myers Squibb, Janssen Pharmaceuticals, and others.
The report suggests that in the next few successful years of clinical research studies associated with the therapy, it will lead to complete transformation in paradigm of cancer treatment. By growing at an accelerated speed in small period of time, the therapy market has also remained successful in getting represented as one of the most exciting approach in the entire biotech space and sector. It is analyzed that about 5-6 bispecific antibodies will gain approval in next 2 years which will further boost the growth of market during the forecast period. As per our analysis, the global bispecific antibody market is expected to surpass US$ 20 Billion by 2028. Geographically, US is expected to dominate the market for next few years owing to the increasing number of cancer patients and highly developed healthcare infrastructure in this region. Apart from this, Europe is also expected to witness a significant growth in this market owing to the increasing numbers cancer patients, rising geriatric population, and growing investment in this field.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366